HBMN:SWX
HBM Healthcare Investments AG
232,00 CHF
arrow_upward
+0,87%(+2,00) 1 pv
29.4., 9.29.32 UTC+2 · CHF
search
Kaikki symbolit
1 pv
5 pv
1 kk
6 kk
YTD
1 v
5 v
MAKS
| Symboli | Hinta | Muutos | Muutos (%) |
|---|
insights_autoLuodaan huippuvinkkejä: HBMN…
Avaa
233,50 CHF
Korkea
233,50 CHF
Matala
232,00 CHF
Markkina-arvo
1,56 mrd.
Keskimääräinen volyymi
6,47 t.
Volyymi
57,00
Osinko
3,23 %
Neljännesvuosittainen osinko
1,87 CHF
Osingon irtoamispäivä
2.7.2025
P/E-luku
6,46
52 viikon ylin
245,50 CHF
52 viikon alin
157,40 CHF
Osakekohtainen tulos (EPS)
35,93 CHF
Liikkeellä olevat osakkeet
6,74 milj.
Uutiset
Eri verkkolähteistä
Seeking Alpha
·
12 minuuttia sitten
Nasdaq 100: AI Bubble Fears Overblown, Bullish Trend Intact Above 26,760 Key Intraday Support
MarketBeat
·
13 minuuttia sitten
Cadiz (NASDAQ:CDZI) Stock Price Passes Below 200-Day Moving Average - Time to Sell?
Simply Wall Street
·
18 minuuttia sitten
Do Elevate Solutions And Motivosity Integration Reveal A Deeper Shift In Paylocity’s (PCTY) Strategy?
Investing.com
·
1 tunti sitten
PureTech Health to delist ADSs from Nasdaq, focus on LSE
Profiili
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Tietoa: HBM Healthcare Investments AG
Toimitusjohtaja-
Työntekijät-
Perustamispäivä12.7.2001
PäätoimipaikkaZug, Zug, Sveitsi
Toimiala-
Sivustohbmhealthcare.com
Tekoälyn luoma sisältö voi sisältää virheitä. Lue lisää